Validation Data Gallery
Tested Applications
| Positive WB detected in | A549 cells, HeLa cells, Cobalt Chloride treated HeLa cells |
| Positive IP detected in | HeLa cells |
| Positive IHC detected in | human stomach cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 24 publications below |
| IHC | See 27 publications below |
| IF | See 9 publications below |
Product Information
11071-1-AP targets Carbonic Anhydrase IX/CA9 in WB, IHC, IF, IP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag1540 Product name: Recombinant human CA9 protein Source: e coli.-derived, PKG Tag: GST Domain: 32-408 aa of BC014950 Sequence: LMPVHPQRLPRMQEDSPLGGGSSGEDDPLGEEDLPSEEDSPREEDPPGEEDLPGEEDLPGEEDLPEVKPKSEEEGSLKLEDLPTVEAPGDPQEPQNNAHRDKEGDDQSHWRYGGDPPWPRVSPACAGRFQSPVDIRPQLAAFCPALRPLELLGFQLPPLPELRLRNNGHSVQLTLPPGLEMALGPGREYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHVVHLSTAFARVDEALGRPGGLAVLAAFLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLDISALLPSDFSRYFQYEGSLTTPPCAQGVIWTVFNQTVMLSAKQLHTLSDTLWGPGDSRLQLNFRATQPLNGRVIEASFPAGVDSSPRAAEPVQLNS 相同性解析による交差性が予測される生物種 |
| Full Name | carbonic anhydrase IX |
| Calculated molecular weight | 459 aa, 50 kDa |
| Observed molecular weight | 50 kDa, 60-70 kDa |
| GenBank accession number | BC014950 |
| Gene Symbol | CA9 |
| Gene ID (NCBI) | 768 |
| RRID | AB_2066528 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q16790 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
CA9 (Carbonic anhydrase 9) may be involved in the control of cell proliferation and transformation and appears to be a novel specific biomarker for a cervical neoplasia (PMID:18703501). It is a tumor-associated antigen that has been shown to have diagnostic utility in identifying cervical dysplasia and carcinoma. The protein is present in the cytoplasmic membrane and the nucleus, with a molecular weight of 50 kDa. The molecular weight of the glycosylated form is approximately 60-70 kDa. (PMID: 31142270, PMID: 31819036)
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for Carbonic Anhydrase IX/CA9 antibody 11071-1-AP | Download protocol |
| WB protocol for Carbonic Anhydrase IX/CA9 antibody 11071-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Proc Natl Acad Sci U S A CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. | ||
Cell Commun Signal KCNJ2/HIF1α positive-feedback loop promotes the metastasis of osteosarcoma | ||
Biomed Pharmacother Para-toluenesulfonamide, a novel potent carbonic anhydrase inhibitor, improves hypoxia-induced metastatic breast cancer cell viability and prevents resistance to αPD-1 therapy in triple-negative breast cancer | ||
Oxid Med Cell Longev Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer | ||
Oxid Med Cell Longev Targeting the Ang2/Tie2 Axis with Tanshinone IIA Elicits Vascular Normalization in Ischemic Injury and Colon Cancer. | ||
Eur J Nucl Med Mol Imaging In vivo three-dimensional evaluation of tumour hypoxia in nasopharyngeal carcinomas using FMT-CT and MSOT. |
